Cellestis Shareholders OK Acquisition by Qiagen | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shareholders of Australian firm Cellestis have approved the proposed acquisition of the firm by Qiagen.

The terms of the deal, which were amended last month to increase the total amount of consideration being paid, was overwhelmingly approved by Cellestis' shareholders with 92 percent of votes in favor of the deal. Roughly 73.9 million votes were cast in favor of the amended scheme, and around 6.5 million votes were against the proposal.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.